| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 21 | 2024 | 864 | 3.480 |
Why?
|
| Heart Failure | 37 | 2024 | 2309 | 3.130 |
Why?
|
| Tissue and Organ Procurement | 4 | 2023 | 232 | 1.570 |
Why?
|
| Heart-Assist Devices | 18 | 2024 | 1028 | 1.490 |
Why?
|
| Graft Rejection | 6 | 2017 | 596 | 1.320 |
Why?
|
| Cardiovascular System | 4 | 2023 | 109 | 1.310 |
Why?
|
| Myocardium | 7 | 2018 | 1029 | 0.920 |
Why?
|
| Complement C4b | 2 | 2017 | 5 | 0.870 |
Why?
|
| Transplantation, Heterologous | 1 | 2024 | 260 | 0.860 |
Why?
|
| Lung Transplantation | 2 | 2024 | 324 | 0.820 |
Why?
|
| Cardiology | 7 | 2022 | 507 | 0.800 |
Why?
|
| Ethics, Clinical | 2 | 2022 | 77 | 0.740 |
Why?
|
| Ethics Consultation | 1 | 2022 | 28 | 0.730 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1712 | 0.650 |
Why?
|
| Decision Making | 3 | 2023 | 671 | 0.620 |
Why?
|
| Dementia | 1 | 2024 | 460 | 0.610 |
Why?
|
| Telemedicine | 2 | 2022 | 448 | 0.610 |
Why?
|
| Palliative Care | 3 | 2024 | 440 | 0.590 |
Why?
|
| Legislation, Medical | 1 | 2018 | 13 | 0.590 |
Why?
|
| Mass Screening | 1 | 2024 | 785 | 0.590 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 42 | 0.570 |
Why?
|
| Advance Care Planning | 3 | 2023 | 40 | 0.570 |
Why?
|
| Humans | 74 | 2024 | 126330 | 0.520 |
Why?
|
| Forecasting | 1 | 2017 | 358 | 0.500 |
Why?
|
| Informed Consent | 1 | 2018 | 336 | 0.490 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 22 | 0.480 |
Why?
|
| Quality of Life | 3 | 2022 | 1954 | 0.480 |
Why?
|
| Serum Sickness | 1 | 2015 | 2 | 0.470 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 55 | 0.460 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2014 | 34 | 0.450 |
Why?
|
| Advance Directives | 3 | 2018 | 33 | 0.440 |
Why?
|
| Patient Positioning | 1 | 2014 | 54 | 0.440 |
Why?
|
| Posture | 1 | 2014 | 149 | 0.430 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 126 | 0.430 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2015 | 218 | 0.430 |
Why?
|
| Sinus of Valsalva | 2 | 2003 | 35 | 0.410 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 121 | 0.400 |
Why?
|
| Tissue Donors | 4 | 2023 | 495 | 0.380 |
Why?
|
| Cardiac Rehabilitation | 2 | 2022 | 24 | 0.380 |
Why?
|
| Aortic Rupture | 2 | 2003 | 118 | 0.380 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 782 | 0.370 |
Why?
|
| Ventricular Function, Left | 6 | 2022 | 520 | 0.370 |
Why?
|
| Cardiomyopathies | 5 | 2021 | 506 | 0.360 |
Why?
|
| Middle Aged | 29 | 2020 | 27031 | 0.360 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2017 | 53 | 0.350 |
Why?
|
| Echocardiography | 5 | 2018 | 1075 | 0.350 |
Why?
|
| Aortic Aneurysm | 2 | 2003 | 232 | 0.340 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2016 | 149 | 0.330 |
Why?
|
| Kidney Transplantation | 4 | 2023 | 658 | 0.320 |
Why?
|
| Heart-Lung Transplantation | 2 | 2022 | 23 | 0.320 |
Why?
|
| United States | 16 | 2024 | 10990 | 0.310 |
Why?
|
| Male | 37 | 2023 | 62031 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 1969 | 0.280 |
Why?
|
| Coronary Care Units | 1 | 2007 | 35 | 0.280 |
Why?
|
| Allografts | 2 | 2018 | 177 | 0.270 |
Why?
|
| Postoperative Complications | 3 | 2016 | 3078 | 0.270 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 171 | 0.270 |
Why?
|
| Antibodies | 1 | 2008 | 370 | 0.260 |
Why?
|
| American Heart Association | 6 | 2024 | 323 | 0.250 |
Why?
|
| Dexamethasone | 1 | 2007 | 276 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2017 | 239 | 0.240 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 435 | 0.240 |
Why?
|
| Aged | 18 | 2024 | 19962 | 0.230 |
Why?
|
| Registries | 4 | 2023 | 1454 | 0.230 |
Why?
|
| Subclavian Artery | 2 | 2015 | 72 | 0.230 |
Why?
|
| Biopsy | 3 | 2018 | 1257 | 0.230 |
Why?
|
| Peptide Fragments | 1 | 2008 | 783 | 0.220 |
Why?
|
| Hospitals, General | 1 | 2003 | 23 | 0.210 |
Why?
|
| Stroke Volume | 5 | 2022 | 501 | 0.210 |
Why?
|
| Hospice Care | 1 | 2023 | 32 | 0.210 |
Why?
|
| Adult | 19 | 2023 | 29802 | 0.210 |
Why?
|
| Cardiac Catheterization | 3 | 2017 | 635 | 0.210 |
Why?
|
| Hospitalization | 3 | 2021 | 1800 | 0.210 |
Why?
|
| Abortion, Legal | 1 | 2023 | 10 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2023 | 16517 | 0.210 |
Why?
|
| Brain Death | 1 | 2023 | 63 | 0.210 |
Why?
|
| Telerehabilitation | 1 | 2022 | 6 | 0.200 |
Why?
|
| Balloon Occlusion | 1 | 2003 | 46 | 0.200 |
Why?
|
| BK Virus | 1 | 2023 | 59 | 0.200 |
Why?
|
| Hemodynamics | 4 | 2017 | 845 | 0.190 |
Why?
|
| Nephritis, Interstitial | 1 | 2023 | 38 | 0.190 |
Why?
|
| Polyomavirus Infections | 1 | 2023 | 90 | 0.190 |
Why?
|
| Female | 29 | 2023 | 67333 | 0.190 |
Why?
|
| Research Report | 4 | 2022 | 77 | 0.190 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 618 | 0.180 |
Why?
|
| Terminal Care | 1 | 2023 | 114 | 0.180 |
Why?
|
| Graft Survival | 1 | 2023 | 540 | 0.180 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1034 | 0.180 |
Why?
|
| Documentation | 1 | 2022 | 113 | 0.170 |
Why?
|
| Disclosure | 1 | 2022 | 150 | 0.170 |
Why?
|
| Swine | 1 | 2024 | 1183 | 0.170 |
Why?
|
| Medical Futility | 1 | 2020 | 37 | 0.170 |
Why?
|
| Kidney Diseases | 1 | 2024 | 487 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2020 | 60 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 294 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2020 | 94 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 79 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 649 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 66 | 0.160 |
Why?
|
| Prealbumin | 2 | 2016 | 26 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 119 | 0.160 |
Why?
|
| Cardiotonic Agents | 2 | 2017 | 140 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 140 | 0.160 |
Why?
|
| Prognosis | 6 | 2019 | 4742 | 0.150 |
Why?
|
| Amyloid | 2 | 2016 | 67 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 890 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2021 | 170 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1129 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5204 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2020 | 225 | 0.150 |
Why?
|
| Point-of-Care Systems | 2 | 2015 | 178 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2015 | 113 | 0.150 |
Why?
|
| Resuscitation Orders | 1 | 2018 | 32 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 56 | 0.140 |
Why?
|
| Medicare | 2 | 2018 | 433 | 0.140 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 367 | 0.140 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 381 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2021 | 393 | 0.140 |
Why?
|
| Patient Preference | 1 | 2019 | 122 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2020 | 313 | 0.140 |
Why?
|
| Mortality | 1 | 2018 | 243 | 0.130 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2016 | 4 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 14 | 0.130 |
Why?
|
| Assisted Circulation | 1 | 2016 | 36 | 0.130 |
Why?
|
| Endocardium | 3 | 2018 | 52 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2017 | 220 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3716 | 0.120 |
Why?
|
| Aortic Valve | 2 | 2016 | 447 | 0.120 |
Why?
|
| Cardiac Volume | 1 | 2015 | 19 | 0.120 |
Why?
|
| Atovaquone | 1 | 2015 | 10 | 0.120 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2015 | 251 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2194 | 0.120 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 194 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2018 | 398 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 239 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2022 | 728 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 768 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 100 | 0.110 |
Why?
|
| Mycoses | 1 | 2016 | 117 | 0.110 |
Why?
|
| Research Design | 1 | 2019 | 709 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 48 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 719 | 0.110 |
Why?
|
| Heart Ventricles | 2 | 2017 | 784 | 0.110 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 33 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1054 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 194 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2014 | 68 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2016 | 473 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 261 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 375 | 0.100 |
Why?
|
| Death | 2 | 2023 | 74 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3622 | 0.100 |
Why?
|
| Survival Rate | 4 | 2019 | 2070 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2015 | 397 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 434 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2017 | 6175 | 0.090 |
Why?
|
| Kidney | 3 | 2024 | 1361 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2011 | 17 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 810 | 0.090 |
Why?
|
| Glycation End Products, Advanced | 1 | 2011 | 26 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 225 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2023 | 12380 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1909 | 0.090 |
Why?
|
| Hypocalcemia | 1 | 2011 | 38 | 0.090 |
Why?
|
| Reoperation | 1 | 2013 | 835 | 0.080 |
Why?
|
| Plasma Exchange | 1 | 2011 | 85 | 0.080 |
Why?
|
| Standard of Care | 2 | 2022 | 130 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 62 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2011 | 240 | 0.080 |
Why?
|
| Sarcomeres | 1 | 2009 | 32 | 0.080 |
Why?
|
| Mutation | 2 | 2016 | 5965 | 0.080 |
Why?
|
| Animals | 2 | 2024 | 34533 | 0.080 |
Why?
|
| HIV Infections | 1 | 2021 | 1906 | 0.080 |
Why?
|
| Hospital Costs | 2 | 2021 | 180 | 0.080 |
Why?
|
| Prosthesis Design | 3 | 2017 | 673 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 2933 | 0.080 |
Why?
|
| Incidence | 4 | 2019 | 3170 | 0.080 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 110 | 0.080 |
Why?
|
| Equipment Design | 2 | 2016 | 595 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2010 | 299 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2010 | 198 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2011 | 434 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 47 | 0.070 |
Why?
|
| Endothelium | 1 | 2008 | 67 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2900 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2007 | 92 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2008 | 184 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 393 | 0.070 |
Why?
|
| Communication | 2 | 2023 | 521 | 0.070 |
Why?
|
| Thermodilution | 1 | 2007 | 11 | 0.070 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2007 | 2 | 0.070 |
Why?
|
| Coronary Circulation | 1 | 2008 | 212 | 0.070 |
Why?
|
| Time Factors | 5 | 2017 | 6334 | 0.070 |
Why?
|
| Natriuretic Agents | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2106 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 2068 | 0.060 |
Why?
|
| Heart | 2 | 2022 | 736 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 171 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2007 | 192 | 0.060 |
Why?
|
| Resource Allocation | 2 | 2020 | 52 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 391 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 349 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2024 | 45 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 314 | 0.060 |
Why?
|
| Physicians, Women | 1 | 2004 | 48 | 0.050 |
Why?
|
| Chicago | 1 | 2003 | 20 | 0.050 |
Why?
|
| Prolapse | 1 | 2003 | 12 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1542 | 0.050 |
Why?
|
| Morals | 1 | 2024 | 69 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2022 | 709 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2003 | 144 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 99 | 0.050 |
Why?
|
| Supreme Court Decisions | 1 | 2023 | 16 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 153 | 0.050 |
Why?
|
| Aortography | 1 | 2003 | 188 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 191 | 0.050 |
Why?
|
| Patient Admission | 1 | 2003 | 186 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 2484 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 82 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 311 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2014 | 355 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 256 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3457 | 0.040 |
Why?
|
| Heart Atria | 1 | 2003 | 322 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2021 | 87 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 397 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 401 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 4323 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2020 | 89 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 260 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 118 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 519 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 771 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2003 | 503 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2007 | 1077 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2015 | 943 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 146 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2017 | 3461 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 4638 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 655 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1293 | 0.030 |
Why?
|
| Weight Loss | 1 | 2021 | 491 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 10375 | 0.030 |
Why?
|
| Anemia | 1 | 2021 | 344 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 375 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 497 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 142 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 37 | 0.030 |
Why?
|
| Thrombin | 1 | 2016 | 60 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 113 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 27 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 46 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 97 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2015 | 51 | 0.030 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 10 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 450 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 828 | 0.030 |
Why?
|
| Image Enhancement | 2 | 2008 | 163 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1325 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 299 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 170 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2015 | 44 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 722 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 84 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2103 | 0.030 |
Why?
|
| Biomarkers | 2 | 2016 | 3153 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3341 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 457 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 477 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 14 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 15 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 19548 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 338 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 741 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 508 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 1296 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 395 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 995 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 315 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 862 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2015 | 981 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2594 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1436 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 7257 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1380 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2009 | 11 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 160 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 622 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 76 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 12681 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2010 | 409 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 438 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 689 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6645 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 4874 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 703 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 203 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1111 | 0.020 |
Why?
|
| Ventriculography, First-Pass | 1 | 2005 | 1 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 1615 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 885 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1204 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9174 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 484 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1029 | 0.010 |
Why?
|
| Career Mobility | 1 | 2004 | 53 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2004 | 85 | 0.010 |
Why?
|
| Mentors | 1 | 2004 | 153 | 0.010 |
Why?
|
| Child | 2 | 2016 | 24766 | 0.010 |
Why?
|
| Family | 1 | 2004 | 566 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8308 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2004 | 1189 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 14221 | 0.010 |
Why?
|